MCID: PDT009
MIFTS: 31

Pediatric Liposarcoma

Categories: Cancer diseases

Aliases & Classifications for Pediatric Liposarcoma

MalaCards integrated aliases for Pediatric Liposarcoma:

Name: Pediatric Liposarcoma 12 15
Childhood Liposarcoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5695
NCIt 50 C8091
UMLS 70 C0279984

Summaries for Pediatric Liposarcoma

MalaCards based summary : Pediatric Liposarcoma, also known as childhood liposarcoma, is related to mediastinum liposarcoma and diffuse lipomatosis. An important gene associated with Pediatric Liposarcoma is DDIT3 (DNA Damage Inducible Transcript 3), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Measles. The drugs Etoposide and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pediatric Liposarcoma

Diseases related to Pediatric Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 mediastinum liposarcoma 10.2 MDM2 CDK4
2 diffuse lipomatosis 10.2 MDM2 CDK4
3 lipoblastoma 10.2 MDM2 CDK4
4 malignant inflammatory fibrous histiocytoma 10.2 MDM2 CDK4
5 paratesticular lipoma 10.2 MDM2 CDK4
6 lipoma of spermatic cord 10.2 MDM2 CDK4
7 adult liposarcoma 10.2 MDM2 CDK4
8 juxtacortical osteosarcoma 10.2 MDM2 CDK4
9 hereditary melanoma 10.2 MDM2 CDK4
10 myositis ossificans 10.2 MDM2 CDK4
11 aortic malignant tumor 10.2 MDM2 CD34
12 retroperitoneal fibrosis 10.2 VIM MDM2
13 conventional central osteosarcoma 10.2 MDM2 CDK4
14 inflammatory liposarcoma 10.2 MDM2 CD34
15 heart sarcoma 10.2 MDM2 CD34
16 malignant mesenchymoma 10.1 MDM2 CD34
17 anaplastic ependymoma 10.1 VIM MDM2
18 heart cancer 10.1 MDM2 CD34
19 intravenous leiomyomatosis 10.1 HMGA2 CD34
20 melanotic neuroectodermal tumor 10.1 VIM MDM2
21 vulvar leiomyoma 10.1 HMGA2 CD34
22 nodular tenosynovitis 10.1 VIM HMGA2
23 glomangiomyoma 10.1 VIM CD34
24 liver fibroma 10.1 VIM CD34
25 cutaneous leiomyosarcoma 10.1 VIM CD34
26 vaginal endometrial stromal sarcoma 10.1 VIM CD34
27 glomangioma 10.1 VIM CD34
28 vagina sarcoma 10.1 VIM CD34
29 benign breast phyllodes tumor 10.1 VIM CD34
30 bladder leiomyoma 10.1 VIM CD34
31 adenoid squamous cell carcinoma 10.1 VIM CD34
32 chondroid lipoma 10.1 HMGA2 FUS
33 central epithelioid sarcoma 10.0 VIM CD34
34 epithelioid sarcoma 10.0 VIM CD34
35 vulvar proximal-type epithelioid sarcoma 10.0 VIM CD34
36 fibrous meningioma 10.0 VIM CD34
37 monophasic synovial sarcoma 10.0 VIM CD34
38 clear cell meningioma 10.0 VIM CD34
39 actinic cheilitis 10.0 TP53 MDM2
40 cheilitis 10.0 TP53 MDM2
41 esophagus verrucous carcinoma 10.0 TP53 MDM2
42 verrucous carcinoma 10.0 TP53 MDM2
43 periosteal osteogenic sarcoma 10.0 TP53 MDM2
44 maxillary sinus adenocarcinoma 10.0 TP53 MDM2
45 pseudosarcomatous fibromatosis 10.0 VIM CD34
46 soft tissue sarcoma 10.0 TP53 MDM2
47 cutaneous fibrous histiocytoma 10.0 VIM CD34
48 adult astrocytic tumour 10.0 TP53 MDM2
49 lip cancer 10.0 TP53 MDM2
50 malignant spiradenoma 10.0 TP53 MDM2

Graphical network of the top 20 diseases related to Pediatric Liposarcoma:



Diseases related to Pediatric Liposarcoma

Symptoms & Phenotypes for Pediatric Liposarcoma

GenomeRNAi Phenotypes related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 10.03 FUS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.03 VIM
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.03 VIM
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 10.03 VIM
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.03 VIM
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 10.03 VIM
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 10.03 VIM
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-3 10.03 FUS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-30 10.03 VIM
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.03 FUS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.03 FUS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.03 FUS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.03 FUS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.03 VIM
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.03 VIM
16 Decreased TP53 mRNA expression GR00389-S-5 9.13 TP53
17 Decreased TP53 mRNA expression GR00389-S-6 9.13 HMGA2 TP53
18 Reduced mammosphere formation GR00396-S 9.02 CD34 CDK4 DDIT3 MDM2 VIM

MGI Mouse Phenotypes related to Pediatric Liposarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 CD34 CDK4 DDIT3 MDM2 TP53

Drugs & Therapeutics for Pediatric Liposarcoma

Drugs for Pediatric Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3 33419-42-0 36462
2
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Tubulin Modulators Phase 3
11 Antibiotics, Antitubercular Phase 3
12 Immunosuppressive Agents Phase 3
13 Alkylating Agents Phase 3
14 Anti-Infective Agents Phase 3
15 Antirheumatic Agents Phase 3
16 Immunologic Factors Phase 3
17 Etoposide phosphate Phase 3
18 Anti-Bacterial Agents Phase 3
19
Isophosphamide mustard Phase 3 100427
20 Antimitotic Agents Phase 3
21 Gastrointestinal Agents Phase 3
22 Neurotransmitter Agents Phase 3
23 Dermatologic Agents Phase 3
24
Histamine Phosphate Phase 3 51-74-1 65513
25 Histamine H1 Antagonists Phase 3
26 Histamine Antagonists Phase 3
27 Anti-Allergic Agents Phase 3
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31 Imatinib Mesylate Phase 2 220127-57-1 123596
32 Protein Kinase Inhibitors Phase 2
33
Liposomal doxorubicin Phase 2 31703
34
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
35
Sargramostim Approved, Investigational Phase 1 123774-72-1, 83869-56-1
36
Molgramostim Investigational Phase 1 99283-10-0
37 Analgesics, Non-Narcotic Phase 1
38 Cyclooxygenase 2 Inhibitors Phase 1
39 Analgesics Phase 1
40 Cyclooxygenase Inhibitors Phase 1
41 Anti-Inflammatory Agents Phase 1
42 Anti-Inflammatory Agents, Non-Steroidal Phase 1
43 Vaccines Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
6 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
7 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
8 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Pediatric Liposarcoma

Genetic Tests for Pediatric Liposarcoma

Anatomical Context for Pediatric Liposarcoma

MalaCards organs/tissues related to Pediatric Liposarcoma:

40
Bone

Publications for Pediatric Liposarcoma

Articles related to Pediatric Liposarcoma:

# Title Authors PMID Year
1
Liposarcoma in children and young adults: a clinicopathologic and molecular study of 23 cases in one of the largest institutions of China. 61
33738541 2021
2
Prognostic factors and survival in pediatric and adolescent liposarcoma. 61
22991488 2012
3
Liposarcoma in children and young adults: a multi-institutional experience. 61
21394894 2011
4
Childhood liposarcoma: a single-institutional twenty-year experience. 61
10505317 1999
5
[Childhood liposarcoma. Diagnostic problems]. 61
3377348 1988
6
[Childhood liposarcoma of the eyelid--a case report]. 61
3723810 1986
7
Childhood liposarcoma. Report of a case and review of the literature. 61
6733687 1984

Variations for Pediatric Liposarcoma

Expression for Pediatric Liposarcoma

Search GEO for disease gene expression data for Pediatric Liposarcoma.

Pathways for Pediatric Liposarcoma

Pathways related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 TP53 MDM2 HMGA2 CDK4
2
Show member pathways
12.51 VIM TP53 MDM2 CDK4
3 12.2 VIM TP53 MDM2 HMGA2
4 12.19 VIM TP53 CDK4
5
Show member pathways
12.13 TP53 MDM2 CDK4
6 12.11 TP53 MDM2 CDK4
7 12.09 VIM TP53 MDM2 CDK4
8 12.05 TP53 MDM2 CDK4
9
Show member pathways
11.98 TP53 MDM2 CDK4
10 11.89 TP53 MDM2 CDK4
11 11.87 TP53 MDM2 CDK4
12 11.73 VIM TP53 CDK4
13 11.68 TP53 MDM2 CDK4
14 11.55 TP53 MDM2 CDK4
15 11.41 TP53 MDM2 CDK4
16 11.3 TP53 MDM2 HMGA2 FUS DDIT3
17 11.15 TP53 DDIT3
18 11.1 TP53 CDK4
19 11.1 TP53 MDM2 CDK4
20 11.08 TP53 MDM2
21 10.98 TP53 MDM2 CDK4
22
Show member pathways
10.9 TP53 MDM2
23 10.89 TP53 MDM2
24 10.64 TP53 MDM2 CDK4

GO Terms for Pediatric Liposarcoma

Cellular components related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-DNA complex GO:0032993 9.16 HMGA2 DDIT3
2 polysome GO:0005844 8.96 VIM FUS
3 transcription factor complex GO:0005667 8.8 TP53 DDIT3 CDK4

Biological processes related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.88 TP53 MDM2 HMGA2 DDIT3
2 positive regulation of transcription, DNA-templated GO:0045893 9.81 TP53 HMGA2 FUS DDIT3
3 cell cycle GO:0007049 9.78 TP53 HMGA2 DDIT3 CDK4
4 negative regulation of gene expression GO:0010629 9.77 TP53 MDM2 CD34
5 response to drug GO:0042493 9.77 TP53 MDM2 CDK4
6 negative regulation of transcription, DNA-templated GO:0045892 9.73 TP53 MDM2 HMGA2 DDIT3
7 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.58 TP53 DDIT3
8 positive regulation of cell cycle GO:0045787 9.57 MDM2 CDK4
9 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070059 9.56 TP53 DDIT3
10 positive regulation of cell cycle arrest GO:0071158 9.55 TP53 HMGA2
11 response to antibiotic GO:0046677 9.54 TP53 MDM2
12 negative regulation of DNA binding GO:0043392 9.52 HMGA2 DDIT3
13 cellular response to gamma radiation GO:0071480 9.49 TP53 MDM2
14 negative regulation of cell cycle arrest GO:0071157 9.46 MDM2 CDK4
15 positive regulation of protein export from nucleus GO:0046827 9.4 TP53 MDM2
16 cardiac septum morphogenesis GO:0060411 9.37 TP53 MDM2
17 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.32 TP53 DDIT3
18 ER overload response GO:0006983 9.26 TP53 DDIT3
19 cellular response to UV-C GO:0071494 9.16 TP53 MDM2
20 positive regulation of gene expression GO:0010628 9.02 VIM TP53 MDM2 HMGA2 CD34
21 cellular response to actinomycin D GO:0072717 8.96 TP53 MDM2

Molecular functions related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.16 TP53 MDM2
2 transcription regulatory region sequence-specific DNA binding GO:0000976 9.13 TP53 HMGA2 DDIT3
3 transcription factor binding GO:0008134 8.92 TP53 HMGA2 DDIT3 CD34

Sources for Pediatric Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....